Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
暂无分享,去创建一个
R. Wells | J. Szer | A. Risitano | A. Gaya | A. Damokosh | J. Lee | S. Langemeijer | S. Nakao | S. Rottinghaus | R. Peffault de Latour | A. Kulasekararaj | Eric S. Bachman | A. Röth | C. Piatek | A. Hill | F. González-Fernández | S. Ortiz | L. Shafner | E. O. Gutierrez | E. Gutierrez
[1] H. Schrezenmeier,et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. , 2019, Blood.
[2] M. Pasnoor,et al. Treatment of Myasthenia Gravis. , 2018, Neurologic clinics.
[3] Zhao-Xue Yu,et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.
[4] C. Bedrosian,et al. Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2017 .
[5] R. Wells,et al. Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies , 2017 .
[6] G. L. Masson,et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.
[7] J. Macneil,et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine , 2017, MMWR. Morbidity and mortality weekly report.
[8] Kuixing Zhang,et al. Atypical Hemolytic Uremic Syndrome: A Brief Review , 2017, Hematology reports.
[9] T. Kinoshita,et al. Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.
[10] J. Szer,et al. Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study , 2016 .
[11] T. Brümmendorf,et al. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)—report on phases I and II , 2016, Annals of Hematology.
[12] P. Ruggenenti,et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] A. Vincent,et al. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms , 2016, F1000Research.
[14] Pierre-Yves Dumas,et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study , 2016, American journal of hematology.
[15] G. Ardissino,et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. , 2016, Kidney international.
[16] H. Echizen,et al. Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. , 2016, Biological & pharmaceutical bulletin.
[17] Yi Wang,et al. First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals , 2015 .
[18] G. Remuzzi,et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies , 2015, Kidney international.
[19] R. Porcher,et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.
[20] R. Brodsky. Paroxysmal nocturnal hemoglobinuria. , 2014, Blood.
[21] P. Hillmen,et al. Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.
[22] G. Remuzzi,et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.
[23] J. Maciejewski,et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria , 2013, British journal of haematology.
[24] W. Gregory,et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.
[25] B. Murtaza,et al. Paroxysmal nocturnal hemoglobinuria. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.
[26] A. Risitano,et al. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents , 2008, Biologics : targets & therapy.
[27] N. Young,et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.
[28] N. Young,et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.
[29] N. Young,et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.